| 摘要 |
The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation. |
| 主权项 |
1. A compound which is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride solvate in its crystalline modification and having at least one group of 2Theta characteristic peak values selected from the following groups:
i. Group A: at least three of the characteristic peak values corresponding to 10.40±0.1, 11.19±0.1, 13.39±0.1, 13.54±0.1, 13.79±0.1, 15.84±0.1, 21.09±0.1, 23.64±0.1, 24.49±0.1 or 25.79±0.1 degrees; ii. Group B: at least three of the characteristic peak values corresponding to 10.49±0.1, 11.73±0.1, 13.12±0.1, 14.46±0.1, 16.24±0.1, 19.32±0.1, 20.05±0.1, 21.75±0.1, 23.50±0.1, or 26.35±0.1 degrees; iii. Group C: at least three of the characteristic peak values corresponding to 5.38±0.1, 9.58±0.1, 10.68±0.1, 13.76±0.1, 15.98±0.1, 22.29±0.1, 23.50±0.1, 24.77±0.1, 26.28±0.1 or 26.52±0.1 degrees; iv. Group D: at least three of the characteristic peak values corresponding to 5.58±0.1, 9.69±0.1, 10.68±0.1, 11.12±0.1, 13.48±0.1, 13.74±0.1, 16.08±0.1, 21.30±0.1, 21.49±0.1 or 24.88±0.1 degrees; v. Group E: at least three of the characteristic peak values corresponding to 8.54±0.1, 12.50±0.1, 13.17±0.1, 18.56±0.1, 19.28±0.1, 19.76±0.1, 20.94±0.1, 21.21±0.1, 25.40±0.1, or 26.26±0.1 degrees; and vi. Group F: at least three of the characteristic peak values corresponding to 5.88±0.1, 11.08±0.1, 17.10±0.1, 18.14±0.1, 21.19±0.1, 22.21±0.1 or 25.47±0.1 degrees. |
